TransCode Therapeutics
RNAZ
3 hedge funds and large institutions have $33.4K invested in TransCode Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.
0.05% more ownership
Funds ownership: 0% → 0.05% (+0.05%)
57% less funds holding
Funds holding: 7 → 3 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
82% less capital invested
Capital invested by funds: $186K → $33.4K (-$152K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$115K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$69.5K |
| 2 |
PCMC
Private Capital Management (Colorado)
Denver,
Colorado
|
-$46.1K |
| 3 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
-$28.6K |
| 4 |
Jane Street
New York
|
-$22.7K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$9.28K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $29.2K | +$115K | +310 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $3.12K | +$9.61K | +26 | +371% |
|
3
Morgan Stanley
New York
| $1.02K | – | – | – |
|
4
Bank of America
Charlotte,
North Carolina
| $13 | – | – | – |
|
|
DB
5
Danske Bank
Copenhagen K,
Denmark
| $3 | – | – | – |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$69.5K | -132 | Closed |
|
|
PCMC
7
Private Capital Management (Colorado)
Denver,
Colorado
| – | -$46.1K | -87 | Closed |
|
|
SSWM
8
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
| – | -$28.6K | -54 | Closed |
|
|
9
Jane Street
New York
| – | -$22.7K | -43 | Closed |
|
|
10
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$9.28K | -18 | Closed |
|
11
Fidelity Investments
Boston,
Massachusetts
| – | -$100 | – | – |
|
RNAZ Hedge Fund Activity: Q4 2024 in Review
3 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q4 2024, worth a combined $33.4K — down 82% from $186K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RNAZ and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, opening a new position worth an estimated $115K. The largest seller was Geode Capital Management, exiting entirely with an estimated $69.5K sold.
- 3 institutional investors held TransCode Therapeutics (RNAZ) as of Q4 2024, down from 7 in Q3 2024.
- Funds reported $33.4K of TransCode Therapeutics stock for Q4 2024, down 82% quarter-over-quarter.
- 1 fund opened new TransCode Therapeutics positions in Q4 2024 and 5 closed out, a net change of -4 holders.
- The largest TransCode Therapeutics buyer in Q4 2024 was UBS Group, an estimated $115K added.
- The largest TransCode Therapeutics seller in Q4 2024 was Geode Capital Management, an estimated $69.5K sold.
Based on aggregated 13F filings for Q4 2024.